Vero Biotech announced that the FDA approved its second-generation Genosyl system for use with rebreathing anesthesia in the operating room setting. Atlanta-based Vero Biotech designed Genosyl for inhaled nitric oxide (iNO) delivery. This approval covers the second-generation Genosyl device. The third-generation device — which recently received FDA approval — has not yet been tested with […]
Vero Biotech
FDA approves next-gen inhaled nitric oxide delivery system from Vero Biotech
Vero Biotech announced that it received FDA approval for its latest-generation tankless inhaled nitric oxide (iNO) delivery system. Atlanta-based Vero Biotech developed its third-generation Genosyl delivery system for respiratory therapists. Its new features include faster dosing, simpler workflow and operational efficiency. Get the full story at our sister site, Drug Delivery Business News.
Abbott promotes Ford to COO | Personnel Moves – October 15, 2018
Abbott (NYSE:ABT) said today that it promoted the head of its medical device division, the healthcare giant’s largest segment, to be its new operations chief. In naming former medical devices VP Robert Ford as COO, Abbott said Ford oversaw the integration of St. Jude Medical and was instrumental in the debut of Abbott’s FreeStyle Libre […]